Ognomy Sleep

What Ognomy Sleep does

Ognomy Sleep (Ognomy Inc.) is a private, Buffalo, NY-based virtual sleep apnea care provider founded in 2019 by Dr. Daniel Rifkin, a sleep medicine specialist with 28 years of clinical experience. The company operates an end-to-end telehealth platform that connects patients in all 50 US states with sleep medicine physicians for consultation, at-home sleep testing, diagnosis, and longitudinal treatment management. Its clinical scope spans CPAP therapy (delivered via a Resmed partnership and Pathway program integration), oral appliance therapy, Inspire hypoglossal nerve stimulation for CPAP-intolerant patients, and — most recently — Zepbound (tirzepatide) prescriptions for adults with moderate-to-severe OSA and obesity via Eli Lilly's LillyDirect marketplace. The platform is device-agnostic on the diagnostic side, integrating five FDA-cleared home sleep testing devices (WatchPAT, ApneaLink Air, SleepImage Ring, EnsoData, NightOwl) plus Oura Ring wearable data, with results interpreted by board-certified sleep specialists and digital sleep reports delivered back to referring primary care providers.

The business model blends per-visit telehealth fees ($124 new patient, $99 follow-up), self-pay HST packages ($320), insurance billing across 200M+ in-network lives (including Medicare), and revenue from device coordination, oral appliance, Inspire implant, and Zepbound prescription services. Go-to-market is hybrid: a direct-to-consumer motion driven by SEO, a 90-second online sleep apnea quiz, and a mobile app, paired with a provider-referral channel (PCPs receive a dedicated portal with EMR integration and digital reports) and channel partnerships with Resmed and Eli Lilly's LillyDirect. The company is ACHC-accredited for home sleep testing, HIPAA-compliant, MedTech Breakthrough 'Best Overall SleepTech Solution' (2026), and reports 25,000+ patients treated, 50,000+ platform visits, 4.9/5 average satisfaction, and 74% CPAP adherence versus an industry average of 45%. Capital raised to date totals roughly $17.7M across three rounds, with the most recent $14.9M round closing in May 2026.

Name

Ognomy Sleep

Legal name

Ognomy Inc.

Website

https://ognomy.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

Ognomy Sleep is a Buffalo-based virtual sleep apnea care platform offering telehealth consultations, at-home sleep testing, and longitudinal treatment (CPAP, oral appliances, Inspire, Zepbound) across all 50 US states, serving 25,000+ patients with in-network coverage for 200M+ lives.

Ownership category

akta.pro rank

Product category

Telehealth Sleep Medicine

NAICS

Offices of Physicians (6211)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011)

akta.pro industry

PRIMARYHLAFABAJ

Ambulatory Sleep Medicine Centers

Healthcare & Life Sciences/Healthcare Providers & Systems/Ambulatory & Outpatient Care Centers

SECONDARYHLAHAGAB

Sleep Diagnostics & Monitoring (PSG/Home Sleep Testing, Actigraphy)

Healthcare & Life Sciences/Medical Devices & Diagnostics/Respiratory & Sleep Therapy Devices

SECONDARYHLAHAGAA

Sleep Apnea Therapy Devices (CPAP/APAP/BiPAP/ASV)

Healthcare & Life Sciences/Medical Devices & Diagnostics/Respiratory & Sleep Therapy Devices

Keywords

• Virtual sleep apnea care
• Telehealth sleep medicine
• Home sleep testing
• PAP therapy services
• Oral appliance therapy

Headquarters

HQ city

Buffalo

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Telehealth Consultations: Revenue from virtual consultations with sleep medicine specialists. New patient appointments are $124, with follow-up appointments at $99 each. Most patients use insurance (Medicare and major insurance plans accepted) with typical copays of $25-$70 for sleep tests.
2. Home Sleep Testing: At-home sleep study kits and interpretation services. Insurance-covered or self-pay at approximately $320 total package including initial consultation, home sleep test, and follow-up consultation.
3. CPAP and Therapy Devices: Revenue from CPAP machines, masks, and accessories through Resmed partnership. Oral appliances and Inspire implant therapy coordination services.
4. Zepbound Prescriptions: Prescription medication for sleep apnea treatment (Zepbound/tirzepatide) as part of comprehensive weight management program for adults with obesity and moderate-to-severe OSA.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Core offering

Ognomy Sleep is a virtual sleep apnea care company that diagnoses and treats obstructive sleep apnea entirely through telehealth. Patients consult board-certified sleep medicine physicians via HIPAA-compliant video, are evaluated using FDA-cleared home sleep testing devices (with Oura Ring data supported), and are then treated with PAP therapy, custom oral appliances, Inspire hypoglossal nerve stimulation, and/or Zepbound weight-loss prescriptions as clinically indicated. The service is in-network with major U.S. payers and licensed in all 50 states.

Product overview

Ognomy Sleep is a virtual sleep apnea care platform offering end-to-end remote diagnosis and treatment. The core platform connects patients with sleep medicine specialists via telehealth consultations, supported by multiple FDA-cleared home sleep testing devices (WatchPAT, ApneaLink Air, SleepImage Ring, EnsoData, NightOwl). Treatment options include CPAP therapy through Resmed partnership, oral appliance therapy, Inspire implant therapy for CPAP-intolerant patients, and Zepbound (tirzepatide) prescriptions for weight management in OSA. The platform integrates with OURA Ring for wearables data, Resmed CPAP devices for therapy monitoring, and LillyDirect for prescription fulfillment. Patients access services through the mobile app or website, with a 90-second sleep apnea quiz as the entry point.

Differentiator

Problem solved

Functional benefit

Products and services

• Ognomy Virtual Sleep Apnea Care End-to-end virtual care pathway for obstructive sleep apnea covering online screening, specialist telehealth consultation, home sleep testing, treatment selection, and ongoing therapy management; available in all 50 U.S. states and in-network with major payers covering 200M+ lives.
• Home Sleep Apnea Testing Multi-device at-home sleep study service using FDA-cleared HSAT devices (WatchPAT, ApneaLink Air, SleepImage, Ectosense/NightOwl), with optional ingestion of biometric signals from the Oura Ring; ordered by Ognomy sleep medicine physicians and shipped to the patient's home.
• Sleep Medicine Telehealth Consultation HIPAA-compliant video consultation with a board-certified sleep medicine specialist for evaluation of suspected obstructive sleep apnea, treatment recommendation, and follow-up management.
• PAP (CPAP/BiPAP) Therapy Program Continuous and bilevel positive airway pressure therapy program for OSA, including device selection, Resmed myAir/Pathway integration for setup and adherence tracking, and ongoing coaching; Ognomy reports a 74% compliance rate versus the ~45% industry average.
• Oral Appliance Therapy Custom-fitted mandibular advancement oral appliances provided as an alternative to PAP for obstructive sleep apnea patients, prescribed and managed by Ognomy sleep medicine physicians.
• Inspire Hypoglossal Nerve Stimulation Therapy Inspire implant therapy program for OSA patients who are intolerant of or refractory to PAP, delivered in partnership with Inspire Medical Systems as a strategic investor and channel partner.
• Zepbound (tirzepatide) Weight-Loss Prescription Program Sleep medicine-led weight-loss prescribing service offering Zepbound (tirzepatide) for OSA patients with comorbid obesity, delivered through Ognomy's integration with the LillyDirect online pharmacy marketplace on a tiered monthly subscription.

Quantifiable outcome

• 74% regular CPAP use among Ognomy patients vs 45% standard average
• +3 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration8 records

Feature3 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Eli Lilly & CompanycoreStrategic or Co-development Partner · 1 December 2024Ognomy Sleep is listed as an independent telehealth provider for sleep apnea care on Eli Lilly's LillyDirect platform. Ognomy patients may be prescribed Zepbound (tirzepatide), the FDA-approved GLP-1 medication for treating moderate-to-severe obstructive sleep apnea in adults with obesity.
• ResmedcoreTechnology or IntegrationOgnomy partners with Resmed and other CPAP device makers to provide patients access to modern CPAP machines with high personalization. Ognomy is part of Resmed's Pathway program, allowing Resmed device users to access virtual sleep apnea care on the Ognomy platform.
• SleepopolisminorGTM or Marketing PartnerSleep apnea education content partnership featuring Ognomy in articles about sleep positions for sleep apnea and other sleep health topics.
• Fox NewsminorGTM or Marketing PartnerMedia coverage featuring Ognomy in health-related articles on topics like sleepwalking and sleep apnea awareness.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Lofta: Direct-to-consumer home sleep apnea testing and treatment platform offering at-home sleep studies and CPAP equipment. Closely comparable business model to Ognomy, with similar patient self-referral, home testing, and therapy fulfillment flow, but without the same integrated telehealth specialist layer across all 50 states.
• BetterNight: Virtual sleep care platform offering telehealth sleep consultations, home sleep testing, and CPAP therapy. Comparable end-to-end virtual sleep care model targeting similar patient segments, with both DTC and provider referral channels.

Broad incumbents

• AdaptHealth: Large national durable medical equipment (DME) provider with a strong CPAP and home respiratory therapy business. Comparable because it serves the same OSA patient population through home-delivered CPAP equipment and supplies, though via a traditional DME model rather than a fully integrated virtual specialist platform.
• Rotech Healthcare: National home medical equipment company with significant respiratory and sleep therapy (CPAP/BiPAP) business. Comparable in treating OSA patients via home-delivered CPAP, but as a traditional DME operator rather than a virtual specialist network.
• Apria Healthcare (Owens & Minor): Major home medical equipment provider, now part of Owens & Minor, with a large CPAP and sleep therapy portfolio. Comparable in serving OSA patients with home-delivered equipment and supplies, though through a more traditional, less virtual-first model.
• Resmed: Global leader in CPAP devices and digital sleep health (myAir app, Pathway program). Comparable as both an incumbent device maker and now a care delivery ecosystem player; Resmed is also an Ognomy partner, making it both competitor and collaborator.
• Inspire Medical Systems: Medical device company behind Inspire hypoglossal nerve stimulation therapy for OSA and an equity investor in Ognomy. Comparable as an OSA treatment provider, especially for CPAP-intolerant patients, and serves as both partner and adjacent incumbent.
• Lincare: Large US provider of home respiratory therapy, including CPAP and home sleep testing services. Comparable in delivering OSA equipment and clinical support to patients in the home, but operating primarily through a traditional DME model.

Emerging players

• Hims & Hers Health: Large direct-to-consumer telehealth platform expanding into sleep and weight loss categories. Comparable in using a national telehealth, D2C, and subscription model, though sleep apnea care is a newer, partial extension of its broader men's and women's health offering.

Others

• Itamar Medical (WatchPAT / ZOLL Itamar): Maker of the WatchPAT home sleep testing device, one of the FDA-cleared HST devices integrated into the Ognomy platform. Comparable as an enabling technology supplier in the OSA diagnostic chain, but not a direct competitor in care delivery.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/ognomyapp
• Facebookfacebook.com/Ognomy
• LinkedInlinkedin.com/company/ognomysleep

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds4 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ognomy Sleep